Role of lymphotoxin in experimental models of infectious diseases: potential benefits and risks of a therapeutic inhibition of the lymphotoxin-beta receptor pathway.
Spahn
Thomas W
TW
Department of General Internal Medicine and Gastroenterology, Marienhospital Osnabrück, Johannisfreiheit 2-4, 49074 Osnabrück, Germany. spahn@uni-muenster.de
Eugster
Hans-Pietro
HP
Fontana
Adriano
A
Domschke
Wolfram
W
Kucharzik
Torsten
T
D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000503:physiopathology; D003141:Communicable Diseases / Q000503:physiopathology*; D005786:Gene Expression Regulation; D006801:Humans; D053259:Lymphotoxin beta Receptor; D008233:Lymphotoxin-alpha / Q000037:antagonists & inhibitors / Q000502:physiology*; D053308:Lymphotoxin-beta; D008565:Membrane Proteins / Q000037:antagonists & inhibitors / Q000502:physiology*; D018124:Receptors, Tumor Necrosis Factor / Q000037:antagonists & inhibitors* / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*
C505886:LTB protein, human; C505697:LTBR protein, human; D053259:Lymphotoxin beta Receptor; D008233:Lymphotoxin-alpha; D053308:Lymphotoxin-beta; D008565:Membrane Proteins; D018124:Receptors, Tumor Necrosis Factor